United States· US:68382-656_1ff75368-1bfd-4173-b0aa-18eca2c97a4f
glyburide
A glibenclamide product containing glyburide, registered in United States by Zydus Pharmaceuticals (USA) Inc.. The same ATC class is registered in 17 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Glibenclamide is registered in 17 of 19 countries.
Countries holding a registration under ATC A10BB01 (glibenclamide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Glibenclamide · ATC A10BB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glibenclamide costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.19 in France to $0.82 in Switzerland — a ×4.4 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glibenclamide · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.82
- IT Italy$0.22
- FR France$0.19
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- GLYBURIDE
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc.
- Country
- United States (US)
- ATC code
- A10BB01
- ATC class
- Glibenclamide
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 12
- ndc1168382-656-01
- ndc1168382-656-05
- ndc1168382-656-06
- ndc1168382-656-10
- ndc116838265601100 TABLET in 1 BOTTLE (68382-656-01)
- ndc116838265605500 TABLET in 1 BOTTLE (68382-656-05)
- ndc11683826560630 TABLET in 1 BOTTLE (68382-656-06)
- ndc1168382656101000 TABLET in 1 BOTTLE (68382-656-10)
- ndc11683826561690 TABLET in 1 BOTTLE (68382-656-16)
- ndc11683826567710 BLISTER PACK in 1 CARTON (68382-656-77) / 10 TABLET in 1 BLISTER PACK (68382-656-30)
- ndc1168382-656-16
- ndc1168382-656-77
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
767 interactions on record for glibenclamide.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glibenclamide · interactions on record
767 records
- 21 severe
- 472 moderate
- 52 minor
- 222 info
Most severe, free to view
- MiconazoleA07AC01severe
- BosentanC02KX01severe
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glibenclamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAmglidia 0.6mg/ml oral suspension with 1ml oral syringeBioprojet UK Ltd
- FranceAMGLIDIA 0,6 mg/mL, suspension buvableAMMTEK
- FinlandAMGLIDIAAMMTek
- BelgiumAmglidia 0.6 mg/mlAMMTeK
- CanadaAPO GLYBURIDE TAB 2.5MGAPOTEX INC
- NorwayGlib-ratiopharm SRatiopharm
- CzechiaAMGLIDIAAMMTeK, Paris
- SpainAMGLIDIA 0,6 mg/ml SUSPENSION ORALAmmtek
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Cyprus · Glibesyn, Glitisol
- Germany · Glib-Ratiopharm S, Glibenclamid Abz
- Spain · Glucolón
- France · Daonil, Glibenclamide Arrow
- United Kingdom (Northern Ireland) · Glibenclamide Activase Pharmaceuticals, Glibenclamide Ennogen Ip
- Greece · Asugrin, Deroctyl
- Iceland · Amglidia
- Italy · Gliben, Gliboral
- Liechtenstein · Amglidia
- Malta · Glitisol
- Norway · Amglidia
- Portugal · Glibenclamida Generis
- Romania · Glibenclamidă Arena
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1fa44d95-4afe-4d1b-938f-2c7e19dd32b9 GET /v1/drugs/1fa44d95-4afe-4d1b-938f-2c7e19dd32b9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "1.25",
"substance": "GLYBURIDE",
"productndc": "68382-656",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA206749",
"marketing_category": "ANDA"
}See everything about glibenclamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.